Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) has earned a consensus rating of “Buy” from the ten ratings firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $15.92.

Several analysts recently commented on DRNA shares. ValuEngine raised shares of Dicerna Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. BidaskClub raised shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, May 4th. HC Wainwright reissued a “hold” rating and set a $14.00 price objective on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 15th. Stifel Nicolaus increased their price objective on shares of Dicerna Pharmaceuticals from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Thursday, August 9th. Finally, Chardan Capital reissued a “hold” rating and set a $14.50 price objective on shares of Dicerna Pharmaceuticals in a research report on Monday, August 13th.

DRNA stock traded down $0.12 during trading on Friday, hitting $15.34. 272,919 shares of the stock traded hands, compared to its average volume of 330,948. Dicerna Pharmaceuticals has a 1 year low of $3.11 and a 1 year high of $16.32. The company has a market capitalization of $841.37 million, a price-to-earnings ratio of -4.19 and a beta of 2.33. The company has a debt-to-equity ratio of 0.14, a quick ratio of 5.40 and a current ratio of 5.40.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.68) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.26). Dicerna Pharmaceuticals had a negative net margin of 1,642.81% and a negative return on equity of 97.39%. The firm had revenue of $1.55 million for the quarter, compared to analysts’ expectations of $1.79 million. research analysts predict that Dicerna Pharmaceuticals will post -1.14 earnings per share for the current fiscal year.

In other news, Director Dennis Langer sold 14,531 shares of the firm’s stock in a transaction dated Wednesday, August 15th. The shares were sold at an average price of $16.00, for a total transaction of $232,496.00. Following the sale, the director now owns 29,064 shares of the company’s stock, valued at approximately $465,024. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 19.85% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. RTW Investments LP boosted its holdings in shares of Dicerna Pharmaceuticals by 0.3% during the 2nd quarter. RTW Investments LP now owns 5,044,813 shares of the biopharmaceutical company’s stock valued at $61,799,000 after acquiring an additional 15,351 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of Dicerna Pharmaceuticals by 839.8% during the 2nd quarter. BlackRock Inc. now owns 2,607,895 shares of the biopharmaceutical company’s stock valued at $31,946,000 after acquiring an additional 2,330,402 shares during the last quarter. Emerald Advisers Inc. PA boosted its holdings in shares of Dicerna Pharmaceuticals by 2,002.5% during the 2nd quarter. Emerald Advisers Inc. PA now owns 603,508 shares of the biopharmaceutical company’s stock valued at $7,393,000 after acquiring an additional 574,804 shares during the last quarter. Emerald Mutual Fund Advisers Trust boosted its holdings in shares of Dicerna Pharmaceuticals by 247.6% during the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 526,859 shares of the biopharmaceutical company’s stock valued at $6,454,000 after acquiring an additional 375,288 shares during the last quarter. Finally, Artal Group S.A. purchased a new stake in shares of Dicerna Pharmaceuticals during the 1st quarter valued at about $4,063,000. 85.89% of the stock is currently owned by hedge funds and other institutional investors.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.

Further Reading: Closed-End Mutual Funds

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.